UCB SA (UCBb)

Overview

UCB SA is a global biopharmaceutical company with a focus on discovering and developing innovative therapies for neurology and immunology diseases. Founded in 1925 and headquartered in Brussels, Belgium, UCB has established itself as a leader in the field of biopharmaceutical research, offering a range of products aimed at improving the lives of patients across the world. The company's dedication to addressing unmet medical needs is evidenced by its robust pipeline of treatments in various stages of development, as well as its strategic partnerships with industry leaders like Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. UCB also participates in contract manufacturing activities, leveraging its expertise to support other entities within the pharmaceutical sector.

Products and Services

UCB SA provides a diverse portfolio of products and services designed to meet the therapeutic needs of patients with neurological and immunological conditions. These include:

• Cimzia: A treatment for a variety of inflammatory diseases mediated by TNF, including ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis.
• Vimpat, Keppra, and Briviact: A group of medications aimed at managing epilepsy.
• Neupro: Designed for the treatment of Parkinson's disease and restless legs syndrome.
• Nayzilam: A nasal spray rescue treatment for epilepsy seizure clusters.
• Zyrtec and Xyzal: Medications for alleviating allergies.
• Evenity: A treatment for osteoporosis in postmenopausal women.
• Bimzelx: A biologic approved for the treatment of plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis.
• Fintepla: Developed for the treatment of Dravet syndrome, a rare and severe form of epilepsy.
• Rozanolixizumab and Zilbrisq: Currently in development for treating myasthenia gravis, an autoimmune disease that affects muscle strength.
• Dapirolizumab pegol: An investigational treatment for systemic lupus erythematosus.
• Fenfluramine: Aimed at treating CDKL5 deficiency disorder and other rare forms of epilepsy.
• Doxecitine: In development for TK2 deficiency disorder, a genetic disorder affecting the muscle.
• STACCATO Alprazolam: A candidate for treating stereotypical prolonged seizures.
• Bepranemab: Under research for Alzheimer's disease therapy.
• Minzasolmin and UCB0222: Targets for Parkinson's disease treatment.
• UCB1381 and UCB9741: In development for treating atropic dermatitis, an inflammatory skin condition.